Edition:
United States

Therapix Biosciences Ltd (TRPX.OQ)

TRPX.OQ on NASDAQ Stock Exchange Capital Market

3.17USD
13 Jul 2018
Change (% chg)

$-0.21 (-6.21%)
Prev Close
$3.38
Open
$3.36
Day's High
$3.36
Day's Low
$3.13
Volume
7,660
Avg. Vol
18,890
52-wk High
$7.67
52-wk Low
$3.13

Chart for

About

Therapix Biosciences Ltd, formerly Nasvax Ltd, is an Israel-based company active in the pharmaceutical sector. The Company develops improved vaccines and immunotherapeutics. Its products include Anti-CD3 oral immunotherapy, directed toward the treatment of inflammatory and autoimmune diseases; Group-common Pneumococcal Vaccine,... (more)
No analyst recommendations are available for .

Overall

Beta: -1.07
Market Cap(Mil.): ₪44.48
Shares Outstanding(Mil.): 139.89
Dividend: --
Yield (%): --

Financials

  TRPX.OQ Industry Sector
P/E (TTM): -- 29.26 33.20
EPS (TTM): -0.31 -- --
ROI: -87.04 13.66 13.23
ROE: -87.04 15.51 15.28

BRIEF-Dual-Listed Therapix To Voluntarily Delist From Tel Aviv Stock Exchange

* DUAL-LISTED THERAPIX TO VOLUNTARILY DELIST FROM TEL AVIV STOCK EXCHANGE

May 09 2018

BRIEF-Therapix Biosciences - Co Terminated Research & License Agreement Between Co, Yissum Research Development Co

* THERAPIX BIOSCIENCES - ON MARCH 18, 2018 CO TERMINATED RESEARCH & LICENSE AGREEMENT BETWEEN CO, YISSUM RESEARCH DEVELOPMENT CO, DATED MARCH 30, 2017 Source text: (https://bit.ly/2F372wh) Further company coverage: (Reuters.Briefs@thomsonreuters.com)

Apr 20 2018

BRIEF-Therapix Biosciences Announces Topline Results Of Phase IIA Study At Yale University For Tourette Syndrome Program

* THERAPIX BIOSCIENCES ANNOUNCES TOPLINE RESULTS OF PHASE IIA STUDY AT YALE UNIVERSITY FOR TOURETTE SYNDROME PROGRAM Source text for Eikon: Further company coverage:

Apr 09 2018

BRIEF-Therapix Biosciences Says U.S. FDA Cleared IND For THX-110 In Treatment Of Chronic Low Back Pain

* THERAPIX BIOSCIENCES - U.S. FDA CLEARED IND FOR THX-110 IN TREATMENT OF CHRONIC LOW BACK PAIN

Mar 20 2018

BRIEF-Therapix Biosciences Expects To Test THX-110 In Early Study In Q2

* THERAPIX BIOSCIENCES LTD - EXPECT TO EVALUATE THX-110 IN A PHASE IIB CLINICAL STUDY IN Q2 OF 2018

Feb 07 2018

Earnings vs. Estimates